Our findings have several implications for the expanding role of GLP-1 RAs in the management of obesity and cardiometabolic disease that underscore the need to understand patient perceptions to guide clinical decision-making, research, and policy efforts. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.